Use: Labeled indications
- INDICATIONS AND USAGE Clonidine hydrochloride is indicated in the treatment of hypertension.
Full indications and usage US FDA label
INDICATIONS AND USAGE Clonidine hydrochloride is indicated in the treatment of hypertension. Clonidine hydrochloride may be employed alone or concomitantly with other antihypertensive agents.
Contraindications
CONTRAINDICATIONS Clonidine hydrochloride tablets USP should not be used in patients with known hypersensitivity to clonidine (see PRECAUTIONS).
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Adults The dose of clonidine hydrochloride USP must be adjusted according to the patient's individual blood pressure response. The following is a general guide to its administration. Initial Dose 0.1 mg tablet twice daily (morning and bedtime). Elderly patients may benefit from a lower initial dose.
Maintenance Dose Further increments of 0.1 mg per day may be made at weekly intervals if necessary until the desired response is achieved. Taking the larger portion of the oral daily dose at bedtime may minimize transient adjustment effects of dry mouth and drowsiness. The therapeutic doses most commonly employed have ranged from 0.2 mg to 0.6 mg per day given in divided doses.
Studies have indicated that 2.4 mg is the maximum effective daily dose, but doses as high as this have rarely been employed. Renal Impairment Patients with renal impairment may benefit from a lower initial dose. Patients should be carefully monitored.Since only a minimal amount of clonidine is removed during routine hemodialysis, there is no need to give supplemental clonidine followingdialysis.
Dosing: Altered kidney function
Renal Impairment Patients with renal impairment may benefit from a lower initial dose. Patients should be carefully monitored.Since only a minimal amount of clonidine is removed during routine hemodialysis, there is no need to give supplemental clonidine followingdialysis.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use Safety and effectiveness in pediatric patients have not been established in adequate and well-controlled trials (see WARNINGS, Withdrawal).
Dosage forms
Philippines
- Tablet: 75 mcg, 150 mcg
- Solution for injection: 150 mcg/mL
Registered products in the Philippines
49 products registered with the Food and Drug Administration (FDA) Philippines list Clonidine as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Clonidine hydrocloride (1 product). Products registered under these spellings are included in the table and marked.
All registered products49
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AlphapresClonidine (as Hydrochloride) | 75 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Medlink Pharma Phils., Inc. | DR-XY40860 | May 10, 2027 | |
CataclonClonidine Hydrochloride | 75 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Corbridge Group Phils., Inc. | DR-XY40812 | Apr 3, 2028 | |
Cataclon 150Clonidine Hydrochloride | 150 mcg TabletAlu/Clear PVC Blister pack x 20's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Corbridge Group Phils., Inc.Importer: Nelpa Lifesciences, Inc. | DRP-12494-01 | Aug 19, 2027 | |
CatamedClonidine Hydrochloride | 150 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Ultramed Pharma, Inc. | DR-XY42851 | Oct 18, 2028 | |
CatamedClonidine Hydrochloride | 75 mcg TabletAlu/Clear PVDC Blister Pack x 10's Box of 100's | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Ultramed Pharma, Inc. | DRP-6756 | Oct 23, 2028 | |
CatapinClonidine Hydrochloride | 150 mcg/mL Solution for Injection (IV)USP Type I Amber Glass Ampoule x 1mL (Box of 10's) | RxVAT-exempt | Ciron Drugs & Pharmaceuticals Pvt. Ltd.India | Phil Pharmawealth, Inc.Trader: Oboi Laboratories | DRP-6580 | Feb 1, 2032 | |
CatapinClonidine hydrochloride | 75 mcg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Sai Parenterals Ltd.TSIIC Industrial Park Hyderabad-Warangal Highway Bhongir Telangana 508116 India | Phil. Pharmawealth, Inc.Importer: Nelpa Lifesciences, Inc. | DRP-12495-02 | Jul 2, 2030 | |
CatapinClonidine Hydrochloride | 75 mcg TabletClear PVDC/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Phil. Pharmawealth, Inc.Trader: Gamot Philippines, Inc. | DRP-6744 | Feb 7, 2031 | |
CatapresClonidine Hydrochloride | 150 mcg TabletAluminum/PVC/PVDC Foil Blister Strip x 10’s Box of 100's | RxVAT-exempt | Delpharm ReimsFrance | Importer: Metro Drug, Inc. | DRP-7888 | Feb 21, 2030 | |
CatapresClonidine Hydrochloride | 75 mcg TabletAluminum/PVC/PVDC foil blister strip x 10’s (Box of 100's) | RxVAT-exempt | Delpharm ReimsFrance | Importer: Metro Drug, Inc. | DRP-7887 | Feb 21, 2030 | |
ChlonbitechClonidine hydrochloride | 150 mcg TabletAlu/Clear PVC blister pack x 20's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-12494-03 | Aug 19, 2027 | |
CLOBASEClonidine Hydrochloride | 150 mcg TabletAlu/PVC/PvDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Base Medico Private LimitedIndia | AMB HK Enterprises, Inc. | DRP-19060 | Oct 22, 2031 | |
ClodinClonidine Hydrochloride | 150mcg TabletAlu/Clear PVC Blister pack x 20's Box of 100's | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | — | DRP-5247 | Dec 6, 2027 | |
ClodinClonidine Hydrochloride | 75 mcg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Drugmaker’s Laboratories Inc.Philippines | — | DRP-6787 | Jul 19, 2028 | |
ClodroxineClonidine hydrochloride | 75 mcg TabletAlu/Clear PVC blister pack x 20's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-12495-01 | Aug 19, 2027 | |
ClonigardClonidine | 75 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DRP-7774 | Mar 19, 2030 | |
ClonigenClonidine (as Hydrochloride) | 150 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-6315 | Mar 2, 2027 | |
ClonigenClonidine | 75 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-6300 | Feb 16, 2028 | |
ClonilifeClonidine Hydrochloride | 150 mcg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) and x 20's (Box of 100's) | RxVAT-exempt | Flourish PharmaIndia | Biophil Medical Equipment and Supplies Trading | DRP-17486 | Jan 12, 2031 | |
ClonilifeClonidine Hydrochloride | 75 mcg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) and x 20's (Box of 100's) | RxVAT-exempt | Flourish PharmaIndia | Biophil Medical Equipment and Supplies Trading | DRP-17485 | Jan 12, 2031 | |
ClonimedClonidine (as Hydrochloride) | 150 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: D.B. Manix International, Inc. | DR-XY40732 | Mar 9, 2027 | |
CloninClonidine Hydrochloride | 150 mcg TabletAlu/PVDC Blister Pack x 10's Box of 30's | RxVAT-exempt | LLOYD LABORATORIES, INC.Philippines | Trader: VITALINK HEALTH PRODUCTS, INC. | DR-XY44304 | Mar 19, 2030 | |
CloninClonidine hydrochloride | 75 mcg TabletAlu/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Vitalink Health Products, Inc. | DR-XY44225 | Feb 23, 2030 | |
ClonipressClonidine Hydrochloride | 150 mcg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, INC. | DRP-2046 | Jun 22, 2027 | |
ClonipressClonidine Hydrochloride | 75 mcg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, INC. | DRP-1868 | Jun 22, 2027 | |
Clonisaph-150Clonidine Hydrochloride | 150 mcg TabletAlu/Clear PVC Blister Pack of 20's (Box of 100's) Alu/Clear PVC Blister Pack of 10's (Box of 100's) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-12494 | Sep 8, 2031 | |
Clonisaph-75Clonidine hydrochloride | 75 mcg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences Inc. | DRP-12495 | Jul 2, 2030 | |
Clonisaph-InfClonidine hydrochloride | 150mcg/mL Solution For Injection (Im/Iv)USP Type I Clear Glass ampoule x 1 mL (Box of 5's and 10's) | RxVAT-exempt | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | FDA-0592800 | Jun 8, 2028 | |
CloniseaClonidine Hydrochloride | 150 mcg / mL Solution for Injection (I.V.)1 mL Type I clear glass ampoule with White Ring on Neck (Box of 10's) | RxVAT-exempt | Kwality Pharmaceuticals Ltd.India | Seapharma International, Inc.Importer: Pharma-Surrey International, Inc. | DRP-14325-01 | Aug 23, 2028 | |
ClonisurClonidine Hydrochloride | 150mcg/mL Solution for Injection (I.V.)1 mL Type I clear glass ampoule with White Ring on Neck (Box of 10's) | RxVAT-exempt | Kwality Pharmaceuticals Ltd.India | Pharma Surrey Internationl, Inc. | DRP-14325 | Aug 23, 2028 | |
ClopresClonidine Hydrochloride | 75 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-10385 | Feb 23, 2030 | |
ClotapressClonidine Hydrochloride | 150 mcg/mL Solution for Injection (IM/IV)1 mL USP Type I Clear Glass Ampoule (Box of 10's) | RxVAT-exempt | Armein Pharmaceuticals Pvt. Ltd.India | Philgen Pharmaceuticals, Inc. | DRP 15354 | Jul 1, 2029 | |
ControlClonidine Hydrochloride | 150 mcg TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-12536 | Aug 30, 2032 | |
CyclodineClonidine Hydrochloride | 150 mcg/mL Solution for Injection (IM/IV)Clear Glass Ampoule x 1 mL (Box of 5's) | RxVAT-exempt | Yung Shin Pharm. Ind. Co., Ltd. - Taichung Youth FactoryTaiwan | Dynasty PharmaceuticalsImporter: Yung Shin (Philippines), Inc. | DRP-1146-01 | Feb 8, 2032 | |
75 mcg TabletAlu/Clear PVC Blister Pack x 7's (Box of 28's); Alu/clear PVC Blister Pack x 10's (Box of 10's) | Rx | Bafna Pharmaceuticals LimitedIndia | MedEthix Inc. | DRP-14355 | Aug 31, 2030 | ||
MelzinClonidine Hydrochloride | 150mcg/mL Solution for Injection (I.M./I.V.)Clear Glass Ampoule x 1mL (Box of 5's) | RxVAT-exempt | Yung Shin Pharm. Ind. Co., Ltd. - Taichung Youth FactoryTaiwan | Yung Shin (Philippines), Inc. | DRP-1146 | Mar 7, 2031 | |
NoneClonidine Hydrochloride | 150 mcg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | RiteMED Phils., Inc.Trader: UNILAB, Inc. | DRP-2046-01 | Jun 22, 2027 | |
NoneClonidine Hydrochloride | 150 mcg TabletAlu/Clear PVC Blister pack x 20's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-5247-2 | Dec 6, 2027 | |
NoneClonidine (as hydrochloride) | 150 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Watsons Personal Care Stores (Philippines), Inc.Trader: Westfield Pharmaceutical, Inc. | DRP-6965 | Apr 3, 2027 | |
NoneClonidine hydrochloride | 75 mcg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100’s) | RxVAT-exempt | Sai Parenterals Ltd.TSIIC Industrial Park Hyderabad-Warangal Highway Bhongir Telangana 508116 India | PharmaVital Corp.Importer: Nelpa Lifesciences Inc. | DRP-12495-03 | Jul 2, 2030 | |
NoneClonidine hydrochloride | 75 mcg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | RiteMed Philippines, Inc.Trader: UNILAB, Inc. | DRP-1868-01 | Jun 22, 2027 | |
NoneClonidine | 75 mcg TabletAlu/Clear PVDC Blister Pack x 10's Box of 100's | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Rose Pharmacy, IncorporatedTrader: Innogen Pharmaceuticals, Inc. | DRP-6300-01 | Feb 16, 2028 | |
NoneClonidine | 75 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Actimed, Inc.Trader: Innogen Pharmaceuticals, Inc. | DRP-6300-02 | Feb 16, 2028 | |
NoneClonidine | 75 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | South Star DrugTrader: Innogen Pharmaceuticals, Inc. | DRP-6300-03 | Feb 16, 2028 | |
NoneClonidine Hydrochloride | 75 mcg TabletAlu/PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Drugmaker’s Laboratories Inc.Philippines | TGP Pharma Inc. | DRP-6787-01 | Jul 19, 2028 | |
NormipressClonidine hydrochloride | 150 mcg TabletAlu/Clear PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Littman Drug Corporation | DR-XY44226 | Feb 23, 2030 | |
TerclodineClonidine (as Hydrochloride) | 150 mcg TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | — | DR-XY40131 | Oct 7, 2028 | |
UnbrandedClonidine Hydrochloride | 75 mcg TabletClear PVDC/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Foramen Products CorporationTrader: Gamot Philippines, Inc. | DRP-6744-01 | Aug 17, 2031 | |
(no brand name)Clonidine Hydrochloride | 150mcg TabletAlu/Clear PVC Blister Pack x 20' s (Box 100' s) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | — | DRP-14144 | Jun 30, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS Withdrawal Patients should be instructed not to discontinue therapy without consulting their physician. Sudden cessation of clonidine treatment has, in some cases, resulted in symptoms such as nervousness, agitation, headache, and tremor accompanied or followed by a rapid rise in blood pressure and elevated catecholamine concentrations in the plasma.
The likelihood of such reactions to discontinuation of clonidine therapy appears to be greater after administration of higher doses or continuation of concomitant beta-blocker treatment and special caution is therefore advised in these situations. Rare instances of hypertensive encephalopathy, cerebrovascular accidents and death have been reported after clonidine withdrawal.
When discontinuing therapy with clonidine hydrochloride, the physician should reduce the dose gradually over 2 to 4 days to avoid withdrawal symptomatology. An excessive rise in blood pressure following discontinuation of clonidine hydrochloride therapy can be reversed by administration of oral clonidine hydrochloride or by intravenous phentolamine.
If therapy is to be discontinued in patients receiving a beta-blocker and clonidine concurrently, the beta-blocker should be withdrawn several days before the gradual discontinuation of clonidine hydrochloride. Because children commonly have gastrointestinal illnesses that lead to vomiting, they may be particularly susceptible to hypertensive episodes resulting from abrupt inability to take medication.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions Clonidine may potentiate the CNS-depressive effects of alcohol, barbiturates or other sedating drugs. If a patient receiving clonidine hydrochloride is also taking tricyclic antidepressants, the hypotensive effect of clonidine may be reduced, necessitating an increase in the clonidine dose. If a patient receiving clonidine is also taking neuroleptics, orthostatic regulation disturbances (e.g., orthostatic hypotension, dizziness, fatigue) may be induced or exacerbated.
Monitor heart rate in patients receiving clonidine concomitantly with agents known to affect sinus node function or AV nodal conduction, e.g. digitalis, calcium channel blockers and beta-blockers. Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concomitantly with diltiazem or verapamil.
Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats (see Toxicology). Based on observations in patients in a state of alcoholic delirium it has been suggested that high intravenous doses of clonidine may increase the arrhythmogenic potential (QT-prolongation, ventricular fibrillation) of high intravenous doses of haloperidol.
Causal relationship and relevance for clonidine oral tablets have not been established. Toxicology In several studies with oral clonidine hydrochloride, a dose-dependent increase in the incidence and severity of spontaneous retinal degeneration was seen in albino rats treated for six months or longer. Tissue distribution studies in dogs and monkeys showed a concentration of clonidine in the choroid.
In view of the retinal degeneration seen in rats, eye examinations were performed during clinical trials in 908 patients before, and periodically after, the start of clonidine therapy. In 353 of these 908 patients, the eye examinations were carried out over periods of 24 months or longer. Except for some dryness of the eyes, no drug-related abnormal ophthalmological findings were recorded and, according to specialized tests such as electroretinography and macular dazzle, retinal function was unchanged.
In combination with amitriptyline, clonidine hydrochloride administration led to the development of corneal lesions in rats within 5 days.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Most adverse effects are mild and tend to diminish with continued therapy. The most frequent (which appear to be dose-related) are dry mouth, occurring in about 40 of 100 patients; drowsiness, about 33 in 100; dizziness, about 16 in 100; constipation and sedation, each about 10 in 100. The following less frequent adverse experiences have also been reported in patients receiving clonidine hydrochloride, but in many cases patients were receiving concomitant medication and a causal relationship has not been established.
Body as a Whole: Fatigue, fever, headache, pallor, weakness, and withdrawal syndrome. Also reported were a weakly positive Coombs’ test and increased sensitivity to alcohol. Cardiovascular: Bradycardia, congestive heart failure, electrocardiographic abnormalities (i.e., sinus node arrest, junctional bradycardia, high degree AV block and arrhythmias), orthostatic symptoms, palpitations, Raynaud’s phenomenon, syncope, and tachycardia.
Cases of sinus bradycardia and atrioventricular block have been reported, both with and without the use of concomitant digitalis. Central Nervous System: Agitation, anxiety, delirium, delusional perception, hallucinations (including visual and auditory), insomnia, mental depression, nervousness, other behavioral changes, paresthesia, restlessness, sleep disorder, and vivid dreams or nightmares.
Dermatological: Alopecia, angioneurotic edema, hives, pruritus, rash, and urticaria. Gastrointestinal: Abdominal pain, anorexia, constipation, hepatitis, malaise, mild transient abnormalities in liver function tests, nausea, parotitis, pseudo-obstruction (including colonic pseudo-obstruction), salivary gland pain, and vomiting.
Genitourinary: Decreased sexual activity, difficulty in micturition, erectile dysfunction, loss of libido, nocturia, and urinary retention. Hematologic: Thrombocytopenia. Metabolic: Gynecomastia, transient elevation of blood glucose or serum creatine phosphokinase, and weight gain. Musculoskeletal: Leg cramps and muscle or joint pain.
Oro-otolaryngeal: Dryness of the nasal mucosa. Ophthalmological: Accommodation disorder, blurred vision, burning of the eyes, decreased lacrimation, and dryness of eyes.
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Teratogenic Effects: Pregnancy Category C. Reproduction studies performed in rabbits at doses up to approximately 3 times the oral maximum recommended daily human dose (MRDHD) of clonidine hydrochloride USP produced no evidence of a teratogenic or embryotoxic potential in rabbits. In rats, however, doses as low as 1/3 the oral MRDHD (1/15 the MRDHD on a mg/m 2 basis) of clonidine were associated with increased resorptions in a study in which dams were treated continuously from 2 months prior to mating.
Increased resorptions were not associated with treatment at the same time or at higher dose levels (up to 3 times the oral MRDHD) when the dams were treated on gestation days 6 to 15. Increases in resorption were observed at much higher dose levels (40 times the oral MRDHD on a mg/kg basis; 4 to 8 times the MRDHD on a mg/m 2 basis) in mice and rats treated on gestation days 1 to 14 (lowest dose employed in the study was 500 mcg/kg).
No adequate, well-controlled studies have been conducted in pregnant women. Clonidine crosses the placental barrier (see CLINICAL PHARMACOLOGY, Pharmacokinetics). Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers As clonidine hydrochloride is excreted in human milk, caution should be exercised when clonidine hydrochloride is administered to a nursing woman.
Pharmacokinetics
Other studies in patients have provided evidence of a reduction in plasma renin activity and in the excretion of aldosterone and catecholamines.
Following intravenous administration, clonidine displays biphasic disposition with a distribution half-life of about 20 minutes and an elimination half-life ranging from 12 to 16 hours.
The half-life increases up to 41 hours in patients with severe impairment of renal function.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Clonidine stimulates alpha-adrenoreceptors in the brain stem. This action results in reduced sympathetic outflow from the central nervous system and in decreases in peripheral resistance, renal vascular resistance, heart rate, and blood pressure. Clonidine hydrochloride acts relatively rapidly. The patient’s blood pressure declines within 30 to 60 minutes after an oral dose, the maximum decrease occurring within 2 to 4 hours.
Renal blood flow and glomerular filtration rate remain essentially unchanged. Normal postural reflexes are intact; therefore, orthostatic symptoms are mild and infrequent. Acute studies with clonidine hydrochloride in humans have demonstrated a moderate reduction (15% to 20%) of cardiac output in the supine position with no change in the peripheral resistance: at a 45° tilt there is a smaller reduction in cardiac output and a decrease of peripheral resistance.
During long term therapy, cardiac output tends to return to control values, while peripheral resistance remains decreased. Slowing of the pulse rate has been observed in most patients given clonidine, but the drug does not alter normal hemodynamic response to exercise. Tolerance to the antihypertensive effect may develop in some patients, necessitating a reevaluation of therapy.
Other studies in patients have provided evidence of a reduction in plasma renin activity and in the excretion of aldosterone and catecholamines. The exact relationship of these pharmacologic actions to the antihypertensive effect of clonidine has not been fully elucidated. Clonidine acutely stimulates growth hormone release in both children and adults, but does not produce a chronic elevation of growth hormone with long-term use.
Pharmacokinetics The pharmacokinetics of clonidine is dose-proportional in the range of 100 to 600 mcg. The absolute bioavailability of clonidine on oral administration is 70% to 80%. Peak plasma clonidine levels are attained in approximately 1 to 3 hours. Following intravenous administration, clonidine displays biphasic disposition with a distribution half-life of about 20 minutes and an elimination half-life ranging from 12 to 16 hours.
The half-life increases up to 41 hours in patients with severe impairment of renal function. Clonidine crosses the placental barrier. It has been shown to cross the blood-brain barrier in rats. Following oral administration about 40% to 60% of the absorbed dose is recovered in the urine as unchanged drug in 24 hours. About 50% of the absorbed dose is metabolized in the liver.
Neither food nor the race of the patient influences the pharmacokinetics of clonidine. The antihypertensive effect is reached at plasma concentrations between about 0.2 and 2.0 ng/mL in patients with normal excretory function. A further rise in the plasma levels will not enhance the antihypertensive effect.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Clonidine 75 mcg Tablet | ₱3.89–₱16.50Reference ₱4.95 | per tablet | DPRI procurement range |
| Clonidine 150 mcg Tablet | ₱4.25–₱40.19Reference ₱11.00 | per tablet | DPRI procurement range |
| Clonidine 150 mcg/mL, 1 mL Ampule | ₱40.19–₱110.90Reference ₱92.44 | per ampule | DPRI procurement range |
| 75 mcg (as hydrochloride) tablet | ₱16.50 | per tablet | PhilHealth GAMOT fixed fee |
| 150 mcg (as hydrochloride) tablet | ₱21.50 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Clonidine |
| PNF listing | Oral: 75 micrograms and 150 micrograms tablet (as hydrochloride) |
| PNF listing | Inj.: 150 micrograms/mL, 1 mL ampul (IV) (as hydrochloride) |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. clonidine hydrochloride · Alembic Pharmaceuticals Limited [US FDA-approved label, version 5, September 30, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88a8db46-0fc9-48cd-b7cc-ac9c9cdea100
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
